Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge Jul 10, 2023 | Uncategorized
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy Feb 24, 2022 | Uncategorized
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Feb 12, 2018 | Uncategorized
Providing a Homing Receptor for CAR Engineered NK Cells – Improving Cellular Immunotherapy for B-Cell Lymphomas Jan 28, 2018 | Uncategorized
